alexa Cervical Cancer Screening Strategies: Not the Test You Take, but the Decision You Make | OMICS International
ISSN: 2161-0932
Gynecology & Obstetrics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Cervical Cancer Screening Strategies: Not the Test You Take, but the Decision You Make

Giorgio Bolis* and Carlo A. Liverani

Department of Gynecology, Università degli Studi di Milano, Italy

*Corresponding Author:
Giorgio Bolis
Department of Gynecology, Fondazione IRCCS
Ospedale Maggiore Policlinico, Università degli Studi di Milano
Via Commenda 12, 20122 Milano, Italy
Tel: +39 338 7257560
E-mail: [email protected]

Received date: Apr 12, 2016; Accepted date: April 14, 2016; Published date: April 19, 2016

Citation: Bolis G, Liverani CA (2016) Cervical Cancer Screening Strategies: Not the Test You Take, but the Decision You Make. Gynecol Obstet (Sunnyvale) 6:e02. doi:10.4172/2161-0932.S5:e02

Copyright: © 2016 Bolis G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Gynecology & Obstetrics

Keywords

Cervical cancer; HPV testing; Cervical lesions

Cervical Cancer Screening Strategies

Starting from May 1, 2017 in Australia the National Cervical Screening Program will shift from cervical cytology every two years, to HPV DNA testing as the sole primary screening test every five years in women aged 25 to 74 years, together with the implementation of an active HPV vaccination program [1]. Conversely in Japan cervical screening using cytology every two years is still being recommended for population-based and opportunistic screening [2]. While Canadian guidelines also recommend cervical screening with cytology every 3 years [3], in Europe cervical cytology is recommended for women under 30-35 years, and HPV testing as the sole primary screening test every 5-10 years for women above 30-35 years [4]. Actually, guidelines do not represent the real situation in each European country. In the Netherlands, screening is well organised and relies on primary HPV testing every 5 years until 40 years of age and every 10 years for women aged 40 and beyond: no screening is provided for women under 30, nor over 60 years of age [5]. Other countries recommend cytology or HPV testing, and differences are marked even within the same country and sometimes within the same region. As a matter of fact in Italy there are regions employing cytology, other regions employing HPV DNA testing, and one local health unit employing HPV mRNA testing as the sole test, while some regions still do not implement organized screening programs [6]. In the U.S. guidelines for cervical cancer screening are well-structured and - in their effort to reach maximum cost-effectiveness - are articulated into several scenarios. Briefly, cytology alone every 3 years is recommended for women under 30 years, while women aged 30 to 65 years may either continue screening with cervical cytology every 3 years, or offered cotesting(cytology + HPV testing) if they want to be screened less frequently [7-9]. Interestingly, European guidelines insist that only one primary test (either cytology or HPV testing) should be used at any given age in cervical cancer screening. In the U.S. until more data and algorithm development will be available, it is judged premature to use HPV testing alone as a valid screening approach [10]. This is the reason why the latest edition of the CDC guidelines published in June 2015 state that HPV testing should not be performed in screening for cervical cancer as a stand-alone test (i.e., without a concurrent Pap test) [11].

As we can see, there is considerable disagreement worldwide about cervical cancer screening strategies between countries that have similar population characteristics. The main problem employing HPV testing based strategies in cervical cancer screening is the fact that both positive and negative HPV results are often misinterpreted or overestimated. An HPV positive, cytology negative woman, should repeat both tests after one year interval. Actually, patients too often tend to undergo immediate colposcopic examination, increasing health care costs and patients’ anxiety, without benefit and potentially resulting in overtreatments. Not rarely clinicians start treating HPV infections detected with molecular tests with surgery, laser, cryotherapy, interferon, 5-florouracil. Then multiple preventive, diagnostic, and therapeutic activities are initiated, both in women and their partners, with strict follow up programs, more tests and more interventions. What many health professionals actually do is test women under 30 years of age; re-screen every 1-2 years; test for low risk HPV types; test anal, vulvar, penile, oral sites; test male partners; test to screen for sexually transmitted infections [12]. All these indications are not recommended and may lead to wrong decisions, with well documented but poorly recognized ill effects. On the other side, a false negative HPV result can occur not infrequently, so that extending rescreening intervals should not be considered safe. In 2009 Kitchener and coll. found that co-testing with HPV test and Pap test was not able to detect a higher rate of high grade lesions than Pap test (ARTISTIC trial) [13]. Surprisingly 3 out of 12 cervical cancers diagnosed in the first two rounds of the trial were preceded by negative HPV results (25%). At the same conclusions arrived Cotton and coll. showing a false negative rate of 22% in women with a high grade lesions or worse who tested HPV negative at baseline (TOMBOLA trial) [14]. Nevertheless, a study designed to evaluate the efficacy of HPV-based strategies in four European randomised controlled trials showed that HPV testing was supposed to provide 60-70% greater protection against cervical cancer compared with cytology [15]. This study has been criticized, because only 11 of 19 cervical cancers detected after enrolment were HPV-positive at baseline; and even among the presumed “prevalent” cases, 16% were HPV-negative at baseline [16], similarly to what we observed in our study showing a 14% false negative HPV testing rate in women treated for histologically confirmed high grade cervical lesions [17]. Another study evaluating the effectiveness of the cobas HPV test found that a total of 59.7% of women who had biopsies that showed abnormal cytology returned a negative result on the cobas HPV test: the authors concluded that the rates of false-negatives in patients with high-grade cervical lesions screened with the cobas HPV test were “unacceptably high” [18]. Eventually, in one study evaluating the concordance among four validated HPV assays, the disagreement was considerable. Among more than five thousand samples, only 29% of them tested positive on all four tests in primary screening samples. In women with abnormal cytology the agreement was 68%, thus implying that referral to colposcopy would depend on which of the four assays has been used in 32% of the cases. In HPV positive, cytology negative women, who represent the vast majority of HPV positive cases, the disagreement was even larger [19].

An underestimated aspect is represented by the simplicity of the new algorithms introduced. Since they should be addressed to all health care providers, they need to be easily remembered and put into practice, in order to reduce waste in the health care system and avoid overtreatments and the downstream consequences they may produce in terms of anxiety, fertility outcomes, recurrence/persistence of the disease, overload of health care services. The sensitivity of cervical cytology - often reported as a little more than 50% - in well established settings is over 80% [20-22]. Both specificity and positive predictive value are higher for cytology than for HPV testing. One study claiming that over long term follow-up the cumulative incidence of high grade lesions was the same for HPV screening and for cytology, led the authors to conclude that the increased sensitivity of HPV test for high grade lesions reflects earlier detection rather than overdiagnosis [23]. Nevertheless they do not discuss the risks of overtreatment this strategy implies, and especially the ethics of communicating an information of a sexually transmitted infection which patients can’t cope with. Concerns on sexual relationships are frequently reported, even after having provided detailed explanations. Besides, there is no urge to detect too early lesions that have a very slow progression rate, and might have been detected with repeat cytology a couple of years later.

Intricate algorithms are not easy to follow and poor adherence to guidelines recommendations affect the prerequisite upon which these new strategies are based. The decision making process can be unintentionally influenced by the test/tests taken, as well as by the patient’s expectations. Both doctors’ attitudes and women’s expectations are difficult to meet with the widespread utilization of different molecular tests not applied consistently according to shared recommendations. The economic, social, and psychological impact of HPV screening seems to have outweighed presumed benefits: the risks are a waste of resources, raise in costs and anxiety, and under-recognition of true disease. If we aim to furtherly reduce cervical cancer mortality, we need to: a) implement HPV vaccination programs (extending the target ages and including males as well as women); b) increase adhesion to screening programs (avoiding overtesting and undertesting); c) implement cytology performance (for example, employing immunocytochemistry techniques); d) guarantee an adequate treatment and follow up to all women diagnosed with a high grade cervical lesion.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 2nd World Congress on Embryology and In Vitro Fertilization March 30-31, 2018 Orlando, USA. Theme: Exploring the Novel Research & Techniques in Reproductive Health
    March 30-31, 2018 Orlando, USA
  • World Congress on Gynecology and Obstetrics
    April 16-17, 2018 Dubai, UAE
  • 7th International Conference on Clinical and Medical Case Reports June 01-02, 2018 Osaka, Japan Theme: Focusing the breakthroughs of case reports in Clinical & Medical Research
    June 01-02, 2018 Osaka, Japan
  • 7th International Conference and Exhibition on Surgery June 21-23, 2018 Dublin, Ireland Theme: Advancements and Endeavours in the Field of Surgery
    June 21-23, 2018 Dublin, Ireland Dublin, Ireland
  • Annual Congress on Research and Innovations in Medicine July 02-03, 2018 Bangkok, Thailand Theme: Current Research and Innovations in Medicine to Improve Human Health
    July 02-03, 2018 Bangkok, Thailand
  • International Conference on Medical and Health Science August 24-25, 2018 Tokyo, JAPAN Theme: Scrutinize the Modish of Medical and Health Science
    August 24-25, 2018 Tokyo, Japan
  • World Summit on Trauma and Reconstructive Surgery Sep 10-11, 2018 Singapore Theme: Expanding new horizons in Trauma and Surgery
    Sep 10-11, 2018 Singapore City, Singapore
  • 6th American Gynecological Surgery Conference September 28-29, 2018 San Antonio | Texas | USA
    September 28-29, 2018 San Antonio, USA
  • World Congress on Fetal and Maternal Medicine October 15-17, 2018 Osaka, Japan Theme: A New Beginning on Fetal, Maternal & Neonatal Medicine
    October 15-17, 2018 Osaka, Japan
  • International Conference on Reproduction and Fertility October 18-19, 2018 Abu Dhabi, UAE
    October 18-19, 2018 Abu Dhabi, UAE

Article Usage

  • Total views: 90
  • [From(publication date):
    specialissue-2016 - Dec 12, 2017]
  • Breakdown by view type
  • HTML page views : 67
  • PDF downloads : 23
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version